Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13339105 | 1.00 | ACHE (0.52) | ACHEBCHETSHRGFERCACNA1B | |
| SCHEMBL2486252 | 0.98 | ACHE (0.51) | ACHEBCHETSHRGFERCACNA1B | |
| SCHEMBL2483662 | 0.98 | ACHE (0.51) | ACHEBCHETSHRGFERCACNA1B | |
| SCHEMBL13339343 | 0.98 | ACHE (0.51) | ACHEBCHETSHRGFERCACNA1B | |
| SCHEMBL16495328 | 0.87 | TSHR (0.62) | ACHETSHRGFERCACNA1BKDM4E | |
| SCHEMBL2484395 | 0.87 | TSHR (0.62) | ACHETSHRGFERCACNA1BKDM4E | |
| SCHEMBL13338348 | 0.87 | TSHR (0.62) | ACHETSHRGFERCACNA1BKDM4E | |
| SCHEMBL2483775 | 0.85 | ACHE (0.61) | ACHETSHRGFERCACNA1BKDM4E | |
| SCHEMBL13338340 | 0.85 | ACHE (0.61) | ACHETSHRGFERCACNA1BKDM4E | |
| SCHEMBL2485226 | 0.85 | ACHE (0.61) | ACHETSHRGFERCACNA1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013019655-A2 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-02-07 | — | — | WO | claimed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | claimed |
| EP-2376425-A2 | KINASE INHIBITOR COMPOUNDS | University of Florida Research Foundation, Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010068710-A2 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20140248634-A1 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140248634-A1 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013019655-A2 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010068710-A2 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | JAK2, JAK1, JAK3 | ACHE 4871/4885BCHE 4733/4885TSHR 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.